UnknownPhase 2

Topical AS101 for Treatment of FAGA (Female Androgenetic Alopecia) in Menopause Women

Israel40 participants

Plain-language summary

The primary objective of this study is to assess the safety and efficacy of topical AS101 as treatment for Female Androgenetic Alopecia (FAGA) in menopause women.

Who can participate

Age range50 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Women in menopause, over 50 years of age. * Clinically diagnosed for AGA, according to Ludwig scale I-II. Exclusion Criteria: * Women treated with chronic medications. * Use of Minoxidil within 3 months prior to entering study. * Women who have underwent hair transplantation. * Use of drugs with androgenic or anti-androgenic effects. * Any other type of hair loss.

What they're measuring

hair density

Trial details

NCT IDNCT00418249

SponsorRabin Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Contact for this trial

Danny Ben Amitai, MD

972-3-9253770

View on ClinicalTrials.gov More Alopecia trials